Request that the FDA maintain the existing regulatory classification of peptide drug products with fewer than 41 Alpha Amino Acids - including GLP-1 receptor agonists and multi-receptor incretin agonists - and to articulate a principled analogous product framework on remand from Eli Lilly & Co. v. Becerra, No. 1:24-cv-01503